March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Association of photoreceptor integrity and visual outcome in Retinal Vein Occlusion (RVO) treated with intravitreal Bevacizumab
Author Affiliations & Notes
  • Manju N. Chandran, Jr.
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Lorraine North
    TC Eye Unit, Frimley Park Hosp Fndtn Trust, Frimley, United Kingdom
  • Subhasree Dhananjayan, Jr.
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Leena Jain, Jr.
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Gulrez Ansari, Jr.
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Narendran Nair, Jr.
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Sidharth Praveen, Jr.
    Salesian College, Farnborough, United Kingdom
  • Geeta Menon, IV
    Ophthalmology, Frimley Park Hospital, Frimley, United Kingdom
  • Footnotes
    Commercial Relationships  Manju N. Chandran, Jr., None; Lorraine North, None; Subhasree Dhananjayan, Jr., None; Leena Jain, Jr., None; Gulrez Ansari, Jr., None; Narendran Nair, Jr., None; Sidharth Praveen, Jr., None; Geeta Menon, IV, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 827. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Manju N. Chandran, Jr., Lorraine North, Subhasree Dhananjayan, Jr., Leena Jain, Jr., Gulrez Ansari, Jr., Narendran Nair, Jr., Sidharth Praveen, Jr., Geeta Menon, IV; Association of photoreceptor integrity and visual outcome in Retinal Vein Occlusion (RVO) treated with intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2012;53(14):827. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the significance of photoreceptor layer status, and external limiting membrane using Spectral Domain Optical CoherenceTomography(SD-OCT), as a prognostic indicator in eyes with macular oedema secondary to retinal vein occlusion (RVO) treated with intravitreal Bevacizumab.

Methods: : Retrospective analysis of 24 eyes of 24 patients who had macular oedema secondary to RVO was carried out. Treatment consisted of three consecutive monthly injections of intravitreal Bevacizumab 1.25mg/0.05ml, followed by retreatment based on OCT findings. Using SD -OCT the status of inner segment and outer segment (IS/OS) photoreceptor junction was assessed as a marker of integrity of photoreceptor layer along with the status of the external limiting membrane (ELM). These findings were correlated with visual acuity (VA) outcome.

Results: : Mean VA was 51.27 letters at baseline and showed a statistically significant improvement of 11.08 letters at 12months(p<0.01 ). Baseline CMT was 426.16 microns and showed a reduction of 287.6 microns at 12 months(p<0.01). Intact ELM and IS/OS lines was found in 95.8% of cases who had a positive visual outcome(p<.01). 4.2% had loss of more than 15 letters and this was associated with disrupted ELM and IS/OS lines. Patients received a mean of 7.3 injections during the 12month follow up period. No systemic or ocular adverse events were reported.

Conclusions: : Integrity of the photoreceptor layer beneath the fovea showed a statistically significant correlation with positive visual acuity outcome in macular oedema secondary to RVO treated with intravitreal Bevacizumab.

Keywords: photoreceptors • vascular occlusion/vascular occlusive disease • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×